NSE: PFIZER | BSE: 500680

Falling Comet

Download real time

4695.00 -9.50 (-0.20%)

High volume today

NSE 12 Mar, 2026 3:31 PM (IST)

21,478.5

Market Cap

High in industry

Beta 1Year

Very Low volatility

Pfizer Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PFIZER, BSE:500680 Pfizer Ltd.

Search Inside the pdf :

Pfizer Ltd.

10 Feb 2026

4695.00

-0.20%

Pfizer Ltd

Buy: Pfizer Ltd.

Recommendation Target

ICICI Direct

Q3FY26 - Strong Revenue growth and margins- Revenues grew ~20% to ~ 645 crore, driven by growth in power brands such as Mucaine (Antacid), Eliquis (CVS), among others. Brands such as Minipress XL (CVS), and Becosules (VMS) also registered moderate growth. On the other hand, there was a de-growth in other power brands such as Corex DX (cough syrup), Dolonex (pain management) and Prevnar 13 (pneumococcal vaccine). EBITDA grew 56% with a strong margin expansion of 824 bps YoY to 35.4%. GPM grew by 169 bps to 65.2%. PAT grew 11% with a...

Pfizer Ltd. is trading below all available SMAs

Pfizer Ltd.

14 Nov 2025

4695.00

-0.20%

Growth momentum accelerating

Buy: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Pfizer’s Q2FY26 revenue grew at a faster pace of 9.1% YoY, surpassing IPM growth of ~8%. Rebound in growth across key brands has helped the company grow faster in the otherwise prevalent sluggish growth scenario for acute therapies.

Pfizer Ltd. is trading at high day volume of 34741.00000.

Pfizer Ltd.

31 Oct 2023

4695.00

-0.20%

Margins balm the pain of a weak season

Accumulate: Pfizer Ltd.

ICICI Securities Limited

Pfizer’s Q2FY24 revenues declined by 9.8%, marred by a weak season for acute products and the recall of three key brands Magnex, Magnamycin and Zoysn. Gross margins contracted 40bps YoY, but recovered 503bps QoQ to 64.4% as the impact of mandated price cuts on NLEM products was partially offset by better product mix.

Pfizer Ltd. is trading at high day volume of 34741.00000.

Pfizer Ltd.

18 Aug 2023

4695.00

-0.20%

Earnings hit by product recall

Accumulate: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer’s Q1FY24 performance was marred by recall of three key brands - Magnex, Magnamycin and Zoysn. These had annual sales of INR 1.4bn in FY23. Gross margin contracted 420bps YoY at 59.4%, also impacted by mandated price cut on NLEM products.

Pfizer Ltd. is trading below all available SMAs

Pfizer Ltd.

17 May 2023

4695.00

-0.20%

Power brands help restore revenue traction

Accumulate: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Q4FY23 marked a turnaround in Pfizer’s performance as the declining revenue trend (down 7% in FY23) was arrested in Q4, which saw a 4% YoY rise. The turnaround was driven by traction in key brands such as Magnex, Corex DX, Dolonex, Minipress XL and Prevenar-13.

Pfizer Ltd. is trading below all available SMAs

Pfizer Ltd.

16 May 2023

4695.00

-0.20%

Pfizer Ltd

Hold: Pfizer Ltd.

Target

ICICI Direct

Pfizer Ltd. has an average target of 6065.00 from 2 brokers.

Pfizer Ltd.

17 Nov 2022

4695.00

-0.20%

Pfizer Ltd

Hold: Pfizer Ltd.

Target

ICICI Direct

Pfizer Ltd. has an average target of 6065.00 from 2 brokers.

Pfizer Ltd.

14 Nov 2022

4695.00

-0.20%

Stringent cost controls lift margins

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer’s Q2FY23 performance beat our estimates on the profitability front driven by strong control over costs. Revenue was flat YoY (+7.5% QoQ) at Rs6.4bn (I-Sec: Rs.6.4bn).

Pfizer Ltd. is trading below all available SMAs

Pfizer Ltd.

08 Aug 2022

4695.00

-0.20%

Cost-control supports margins

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Pfizer’s Q1FY23 performance beat our estimates on the profitability front driven
by strong control over costs. Revenues declined 20.9% YoY (+7.9% QoQ) to Rs 5.9bn (I-Sec: Rs 5.9bn) on a high covid-led base.

Pfizer Ltd. is trading below all available SMAs

Is Pfizer Ltd. worth buying?

213 Votes:

Buy 74.18%

Sell 14.55%

Hold 11.27%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf